{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:44:21Z","timestamp":1791938661736,"version":"4.3.4"},"reference-count":22,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Existing pharmacological treatments for insomnia have significant limitations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the effective dose range, safety, and tolerability of the novel selective orexin-2 receptor antagonist seltorexant in insomnia disorder.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This randomized, double-blind, active- and placebo-controlled, dose-finding, polysomnography study was conducted from November 2017 to April 2019 at 55 sites in 6 countries and analyzed in August 2019. The timeline for submission of this data for publication was impacted by internal strategic decision-making. Adults (aged 18-64 years) and older adults (aged 65-85 years) with insomnia (Insomnia Severity Index score \u226515) and no psychiatric comorbidity were included.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>Participants were randomized 1:1:1:1:1 to receive nightly oral-seltorexant (5 mg, 10 mg, or 20 mg), placebo, or zolpidem (5-10 mg) for 14 days.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Primary and key secondary outcomes included the dose-response relationship of night 1 latency to persistent sleep (LPS) and wake after sleep onset over the first 6 hours (WASO-6). Other secondary outcomes included night 13 LPS and WASO-6. Due to asymmetrical distributions of LPS and WASO-6 at baseline, log transformation was applied and results were expressed as back-transformed least-squares mean (LSM) ratios for comparisons between groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 364 participants (mean [SD] age, 57.8 [12.4] years; 246 [67.6%] female) received seltorexant, 5 mg (n\u2009=\u200971), 10 mg (n\u2009=\u200974), or 20 mg (n\u2009=\u200971); placebo (n\u2009=\u200975); or zolpidem (n\u2009=\u200973). The night 1 dose-response relationship for LPS was significant (with trend test <jats:italic>t<\/jats:italic> statistics \u22653.99 and adjusted <jats:italic>P<\/jats:italic> values &amp;amp;lt;.001 for all 4 prespecified models), with greater improvements in seltorexant, 10 mg and 20 mg, vs placebo (10 mg: LSM ratio, 0.64; 90% CI, 0.51-0.81; 20 mg: LSM ratio, 0.51; 90% CI, 0.41-0.64) and in seltorexant, 20 mg, vs zolpidem (LSM ratio, 0.71; 90% CI, 0.57-0.88). The night 1 dose-response relationship for WASO-6 was also significant, with trend test <jats:italic>t<\/jats:italic> statistics \u22653.99 and adjusted <jats:italic>P<\/jats:italic> values &amp;amp;lt;.001 for all 4 prespecified models (seltorexant, 10 mg: LSM ratio, 0.68; 90% CI, 0.55-0.85; seltorexant, 20 mg: LSM ratio, 0.60; 90% CI, 0.48-0.74). Night 1 LPS and WASO-6 improvements were maintained on night 13 for seltorexant, 10 mg and 20 mg, but diminished for zolpidem. On night 13, compared with zolpidem, seltorexant, 10 mg and 20 mg, improved LPS by 30% and 28%, respectively, and seltorexant, 20 mg, improved WASO-6 by 31%. Treatment-emergent adverse events (TEAEs) were lower across the combined seltorexant doses (73\/216 [33.8%]) relative to placebo (37\/75 [49.3%]) and zolpidem (31\/73 [42.5%]). Two participants experienced serious TEAEs during the double-blind phase (1 in the seltorexant, 20 mg, group and 1 in the zolpidem group). Three participants in the seltorexant, 5 mg, and 1 in the seltorexant, 20 mg, group experienced asymptomatic electrocardiogram-related TEAEs leading to discontinuation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>Among participants with insomnia in this study, seltorexant, 10 mg and 20 mg, improved sleep initiation and maintenance throughout 14 days of treatment. Seltorexant was generally well tolerated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03375203?id=NCT03375203&amp;amp;amp;rank=1\">NCT03375203<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2025.1999","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T15:00:38Z","timestamp":1755097238000},"page":"967","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and Safety of Seltorexant in Insomnia Disorder"],"prefix":"10.1001","volume":"82","author":[{"given":"Sofie","family":"Mesens","sequence":"first","affiliation":[{"name":"Johnson & Johnson, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Krystal","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rama","family":"Melkote","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Raritan, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Xu","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Titusville, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gahan","family":"Pandina","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Titusville, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay B.","family":"Saoud","sequence":"additional","affiliation":[{"name":"Minerva Neurosciences, Waltham, Massachusetts"},{"name":"Now with Pharmaceutical Product Development Associates, Groton, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remy","family":"Luthringer","sequence":"additional","affiliation":[{"name":"Minerva Neurosciences, Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Savitz","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Titusville, New Jersey"},{"name":"Now with Weill Cornell Medical College, White Plains, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne C.","family":"Drevets","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"yoi250038r1","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.smrv.2010.01.003","article-title":"Societal costs of insomnia.","volume":"14","author":"L\u00e9ger","year":"2010","journal-title":"Sleep Med Rev"},{"issue":"2","key":"yoi250038r2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jsmc.2022.03.003","article-title":"Epidemiology of insomnia: prevalence, course, risk factors, and public health burden.","volume":"17","author":"Morin","year":"2022","journal-title":"Sleep Med Clin"},{"issue":"3","key":"yoi250038r3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ecl.2013.05.001","article-title":"Sleep disorders and the development of insulin resistance and obesity.","volume":"42","author":"Mesarwi","year":"2013","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"5","key":"yoi250038r4","first-page":"S7","article-title":"Insomnia: definition, prevalence, etiology, and consequences.","volume":"3","author":"Roth","year":"2007","journal-title":"J Clin Sleep Med"},{"issue":"11","key":"yoi250038r5","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1016\/j.clinthera.2016.09.010","article-title":"Review of safety and efficacy of sleep medicines in older adults.","volume":"38","author":"Schroeck","year":"2016","journal-title":"Clin Ther"},{"issue":"1","key":"yoi250038r6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.smrv.2009.04.002","article-title":"The hyperarousal model of insomnia: a review of the concept and its evidence.","volume":"14","author":"Riemann","year":"2010","journal-title":"Sleep Med Rev"},{"issue":"3","key":"yoi250038r7","doi-asserted-by":"publisher","first-page":"37400","DOI":"10.52965\/001c.37400","article-title":"Daridorexant for the treatment of insomnia.","volume":"10","author":"Robinson","year":"2022","journal-title":"Health Psychol Res"},{"key":"yoi250038r8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3389\/fnins.2014.00028","article-title":"Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism.","volume":"8","author":"Dugovic","year":"2014","journal-title":"Front Neurosci"},{"key":"yoi250038r9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/issn.0300-5186","article-title":"Hypocretin\/orexin receptor pharmacology and sleep phases.","volume":"45","author":"Sun","year":"2021","journal-title":"Front Neurol Neurosci"},{"issue":"1","key":"yoi250038r10","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1124\/jpet.109.152009","article-title":"Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat.","volume":"330","author":"Dugovic","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"yoi250038r11","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1124\/jpet.115.225466","article-title":"Characterization of JNJ-42847922, a selective orexin-2 receptor antagonist, as a clinical candidate for the treatment of insomnia.","volume":"354","author":"Bonaventure","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"yoi250038r12","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1177\/0269881118773745","article-title":"A randomized phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity.","volume":"32","author":"De Boer","year":"2018","journal-title":"J Psychopharmacol"},{"issue":"12","key":"yoi250038r13","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/ijnp\/pyab050","article-title":"Efficacy and safety of seltorexant as adjunctive therapy in major depressive disorder: a phase 2b, randomized, placebo-controlled, adaptive dose-finding study.","volume":"24","author":"Savitz","year":"2021","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"yoi250038r14","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1177\/0269881118822258","article-title":"The selective orexin-2 receptor antagonist seltorexant improves sleep: an exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia.","volume":"33","author":"Brooks","year":"2019","journal-title":"J Psychopharmacol"},{"issue":"6","key":"yoi250038r15","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1038\/s41380-024-02846-5","article-title":"Treatment effect and safety of seltorexant as monotherapy for patients with major depressive disorder: a randomized, placebo-controlled clinical trial.","volume":"30","author":"Mesens","year":"2025","journal-title":"Mol Psychiatry"},{"issue":"23","key":"yoi250038r17","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1212\/WNL.0b013e31827688ee","article-title":"Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.","volume":"79","author":"Herring","year":"2012","journal-title":"Neurology"},{"key":"yoi250038r18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e8343","article-title":"Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration.","volume":"345","author":"Huedo-Medina","year":"2012","journal-title":"BMJ"},{"key":"yoi250038r19","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2020.101332","article-title":"Effects of orexin receptor antagonism on human sleep architecture: a systematic review.","volume":"53","author":"Clark","year":"2020","journal-title":"Sleep Med Rev"},{"issue":"1","key":"yoi250038r20","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41398-019-0553-z","article-title":"The selective orexin-2 antagonist seltorexant (JNJ-42847922\/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder.","volume":"9","author":"Recourt","year":"2019","journal-title":"Transl Psychiatry"},{"issue":"3","key":"yoi250038r22","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1089\/jwh.2020.8349","article-title":"Sleep health in women of childbearing age.","volume":"29","author":"Redeker","year":"2020","journal-title":"J Womens Health (Larchmt)"},{"key":"yoi250038r16","unstructured":"Ambien. Prescribing information. Sanofi-Aventis; 2014. Accessed May 9, 2025. https:\/\/products.sanofi.us\/ambien\/ambien.pdf"},{"key":"yoi250038r21","unstructured":"A study to evaluate the effects of single-dose seltorexant on electrocardiogram intervals in healthy adult participants. ClinicalTrials.gov identifier: NCT03494907. Updated March 1, 2024. Accessed December 11, 2024. https:\/\/clinicaltrials.gov\/study\/NCT03494907"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2837250\/jamapsychiatry_mesens_2025_oi_250038_1759153286.81479.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:00:55Z","timestamp":1759330855000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2837250"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.1999","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,1]]}}}